ClinicalTrials.gg
CompletedNCT03691779Updated Oct 22, 2021Results posted

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 21 sites in 5 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-10-22.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
17th of 23
71 · median 120
Started
2018
with 1 other
Phase 3
19 of 23
none open now
Registered
3rd of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 17th largest by enrollment, is one of 2 that started in 2018, is one of 19 in phase 3, and was the 3rd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-445, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects 6 through 11 years of age with F/F and F/MF genotypes.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Homozygous or heterozygous for F508del mutation (F/F or F/MF genotypes)
  • (FEV1) value ≥40% of predicted mean for age, sex, and height.

Key Exclusion Criteria:

  • cirrhosis with or without portal hypertension
  • Lung infection with organisms associated with a more rapid decline in pulmonary status.
  • Solid organ or hematological transplantation.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Part A: ELX/TEZ/IVA

    Participants in Part A received ELX 100 milligrams (mg) once daily (qd)/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) in the treatment period for 15 days.

    Drug: ELX/TEZ/IVA · Drug: IVA

  • Experimental
    Part B: ELX/TEZ/IVA

    Participants in Part B weighing less than (\<) 30 kilograms (kg) at Day 1 received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h and participants weighing greater than equals to (\>=) 30 kg at Day 1 received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed-dose combination tablet orally once daily in the morning.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    IVA tablet orally once daily in the evening.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA

    Time frame: Part A: Day 15

  2. Part A: Observed Pre-dose Plasma Concentration (Ctrough) of ELX, TEZ, and IVA

    Time frame: Part A: Day 15

  3. Part A: Area Under the Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24h) of ELX, TEZ, and IVA

    Time frame: Part A: Day 15

  4. Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Part B: Day 1 Through Safety Follow-up Visit (up to Week 28)

Secondary outcomes

  1. Part A: Cmax of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)

    Time frame: Part A: Day 15

  2. Part A: Ctrough of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)

    Time frame: Part A: Day 15

  3. Part A: AUC0-24h of ELX Metabolite (M23-ELX) and TEZ Metabolite (M1-TEZ)

    Time frame: Part A: Day 15

  4. Part A: Area Under the Concentration Versus Time Curve From 0 to 6 Hours (AUC0-6h) of IVA Metabolite (M1-IVA)

    The AUC data was analyzed for up to 6 hours for IVA metabolite (M1-IVA). Therefore, AUC0-6h is reported for M1-IVA metabolite.

    Time frame: Part A: Day 15

  5. Part A: Safety and Tolerability as Assessed by Number of Participants With TEAEs and SAEs

    Time frame: Part A: Day 1 Through Safety Follow-up Visit (up to Day 43)

  6. Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Part B: From Baseline Through Week 24

  7. Part B: Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: Part B: From Baseline Through Week 24

  8. Part B: Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Part B: From Baseline Through Week 24

  9. Part B: Absolute Change in Body Mass Index (BMI)

    BMI was defined as weight in kg divided by squared height in meters (m\^2).

    Time frame: Part B: From Baseline at Week 24

  10. Part B: Absolute Change in BMI For-Age Z-Score

    BMI was defined as weight in kg divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

    Time frame: Part B: From Baseline at Week 24

  11. Part B: Absolute Change in Weight

    Time frame: Part B: From Baseline at Week 24

  12. Part B: Absolute Change in Weight-for-age Z-Score

    The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

    Time frame: Part B: From Baseline at Week 24

  13. Part B: Absolute Change in Height

    Time frame: Part B: From Baseline at Week 24

  14. Part B: Absolute Change in Height-for-Age Z-Score

    The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

    Time frame: Part B: From Baseline at Week 24

  15. Part B: Drug Acceptability Assessment Using Modified Facial Hedonic Scale

    The study drug acceptability (participant reaction) was assessed by a visual analog scale that incorporates a 5 point facial hedonic scale (Liked it Very Much, Liked it a Little, Not sure, Disliked it a Little, Disliked it Very Much). Number of participants with the indicated categorical response in the drug acceptability assessment were reported.

    Time frame: Part B: At Week 24

  16. Part B: Number of Pulmonary Exacerbations Events

    Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria. The total number of pulmonary exacerbations events across all participants were reported.

    Time frame: Part B: From Baseline Through Week 24

  17. Part B: Number of CF Related Hospitalizations

    The total number of CF related hospitalization events across all participants were reported.

    Time frame: Part B: From Baseline Through Week 24

  18. Part B: Ctrough of ELX, ELX Metabolite (M23-ELX), TEZ, TEZ Metabolite (M1-TEZ), IVA and IVA Metabolite (M1-IVA)

    Time frame: Part B: At Week 4

  19. Part B: Absolute Change in Lung Clearance Index 2.5 (LCI2.5)

    LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

    Time frame: Part B: From Baseline Through Week 24

07

Results

Posted Oct 22, 2021

Participant flow

The study was conducted in 2 parts, Part A and Part B. All results were planned to be analyzed and reported separately for Part A and Part B of the study.

Part A (15 Days)
Participant flow — Part A (15 Days)
MilestonePart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Started160
Completed160
Not completed00
Part B (24 Weeks)
Participant flow — Part B (24 Weeks)
MilestonePart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Started066
Completed064
Not completed02
Withdrew: Adverse event01
Withdrew: Withdrawal of consent (not due to ae)01

Outcome measures

PrimaryPart A: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA
Time frame:
Part A: Day 15
Reported as:
Mean · microgram per milliliter (mcg/mL)
Part A: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA
microgram per milliliter (mcg/mL)Part A: ELX/TEZ/IVA
ELX6.13 ± 1.52
TEZ6.93 ± 1.96
IVA1.01 ± 0.281
PrimaryPart A: Observed Pre-dose Plasma Concentration (Ctrough) of ELX, TEZ, and IVA
Time frame:
Part A: Day 15
Reported as:
Mean · mcg/mL
Part A: Observed Pre-dose Plasma Concentration (Ctrough) of ELX, TEZ, and IVA
mcg/mLPart A: ELX/TEZ/IVA
ELX2.86 ± 1.37
TEZ1.06 ± 0.366
IVA0.297 ± 0.173
PrimaryPart A: Area Under the Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24h) of ELX, TEZ, and IVA
Time frame:
Part A: Day 15
Reported as:
Mean · hour*microgram per milliliter (h*mcg/mL)
Part A: Area Under the Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24h) of ELX, TEZ, and IVA
hour*microgram per milliliter (h*mcg/mL)Part A: ELX/TEZ/IVA
ELX107 ± 28.7
TEZ58.4 ± 13.5
IVA8.12 ± 2.93
PrimaryPart B: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Part B: Day 1 Through Safety Follow-up Visit (up to Week 28)
Reported as:
Number · participants
Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsPart B: ELX/TEZ/IVA
Participants With TEAEs65
Participants With SAEs1
SecondaryPart A: Cmax of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame:
Part A: Day 15
Reported as:
Mean · mcg/mL
Part A: Cmax of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
mcg/mLPart A: ELX/TEZ/IVA
M23-ELX1.60 ± 0.657
M1-TEZ6.26 ± 1.54
M1-IVA2.36 ± 0.694
SecondaryPart A: Ctrough of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame:
Part A: Day 15
Reported as:
Mean · mcg/mL
Part A: Ctrough of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
mcg/mLPart A: ELX/TEZ/IVA
M23-ELX1.30 ± 0.585
M1-TEZ4.64 ± 1.36
M1-IVA0.890 ± 0.460
SecondaryPart A: AUC0-24h of ELX Metabolite (M23-ELX) and TEZ Metabolite (M1-TEZ)
Time frame:
Part A: Day 15
Reported as:
Mean · h*mcg/mL
Part A: AUC0-24h of ELX Metabolite (M23-ELX) and TEZ Metabolite (M1-TEZ)
h*mcg/mLPart A: ELX/TEZ/IVA
M23-ELX35.6 ± 13.2
M1-TEZ133 ± 30.4
SecondaryPart A: Area Under the Concentration Versus Time Curve From 0 to 6 Hours (AUC0-6h) of IVA Metabolite (M1-IVA)

The AUC data was analyzed for up to 6 hours for IVA metabolite (M1-IVA). Therefore, AUC0-6h is reported for M1-IVA metabolite.

Time frame:
Part A: Day 15
Reported as:
Mean · h*mcg/mL
Part A: Area Under the Concentration Versus Time Curve From 0 to 6 Hours (AUC0-6h) of IVA Metabolite (M1-IVA)
h*mcg/mLPart A: ELX/TEZ/IVA
Part A: Area Under the Concentration Versus Time Curve From 0 to 6 Hours (AUC0-6h) of IVA Metabolite (M1-IVA)9.41 ± 3.06
SecondaryPart A: Safety and Tolerability as Assessed by Number of Participants With TEAEs and SAEs
Time frame:
Part A: Day 1 Through Safety Follow-up Visit (up to Day 43)
Reported as:
Number · participants
Part A: Safety and Tolerability as Assessed by Number of Participants With TEAEs and SAEs
participantsPart A: ELX/TEZ/IVA
Participants With TEAEs12
Participants With SAEs0
SecondaryPart B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Part B: From Baseline Through Week 24
Reported as:
Least squares mean · percentage points
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsPart B: ELX/TEZ/IVA
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)10.2 (7.9 to 12.6)
SecondaryPart B: Absolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
Part B: From Baseline Through Week 24
Reported as:
Least squares mean · millimole per liter (mmol/L)
Part B: Absolute Change in Sweat Chloride (SwCl)
millimole per liter (mmol/L)Part B: ELX/TEZ/IVA
Part B: Absolute Change in Sweat Chloride (SwCl)-60.9 (-63.7 to -58.2)
SecondaryPart B: Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Part B: From Baseline Through Week 24
Reported as:
Least squares mean · units on a scale
Part B: Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score
units on a scalePart B: ELX/TEZ/IVA
Part B: Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score7.0 (4.7 to 9.2)
SecondaryPart B: Absolute Change in Body Mass Index (BMI)

BMI was defined as weight in kg divided by squared height in meters (m\^2).

Time frame:
Part B: From Baseline at Week 24
Reported as:
Least squares mean · kg/m^2
Part B: Absolute Change in Body Mass Index (BMI)
kg/m^2Part B: ELX/TEZ/IVA
Part B: Absolute Change in Body Mass Index (BMI)1.02 (0.76 to 1.28)
SecondaryPart B: Absolute Change in BMI For-Age Z-Score

BMI was defined as weight in kg divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

Time frame:
Part B: From Baseline at Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change in BMI For-Age Z-Score
z-scorePart B: ELX/TEZ/IVA
Part B: Absolute Change in BMI For-Age Z-Score0.37 (0.26 to 0.48)
SecondaryPart B: Absolute Change in Weight
Time frame:
Part B: From Baseline at Week 24
Reported as:
Least squares mean · kg
Part B: Absolute Change in Weight
kgPart B: ELX/TEZ/IVA
Part B: Absolute Change in Weight3.0 (2.5 to 3.5)
SecondaryPart B: Absolute Change in Weight-for-age Z-Score

The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

Time frame:
Part B: From Baseline at Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change in Weight-for-age Z-Score
z-scorePart B: ELX/TEZ/IVA
Part B: Absolute Change in Weight-for-age Z-Score0.25 (0.16 to 0.33)
SecondaryPart B: Absolute Change in Height
Time frame:
Part B: From Baseline at Week 24
Reported as:
Least squares mean · centimeters (cm)
Part B: Absolute Change in Height
centimeters (cm)Part B: ELX/TEZ/IVA
Part B: Absolute Change in Height2.3 (1.9 to 2.7)
SecondaryPart B: Absolute Change in Height-for-Age Z-Score

The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

Time frame:
Part B: From Baseline at Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change in Height-for-Age Z-Score
z-scorePart B: ELX/TEZ/IVA
Part B: Absolute Change in Height-for-Age Z-Score-0.05 (-0.12 to 0.01)
SecondaryPart B: Drug Acceptability Assessment Using Modified Facial Hedonic Scale

The study drug acceptability (participant reaction) was assessed by a visual analog scale that incorporates a 5 point facial hedonic scale (Liked it Very Much, Liked it a Little, Not sure, Disliked it a Little, Disliked it Very Much). Number of participants with the indicated categorical response in the drug acceptability assessment were reported.

Time frame:
Part B: At Week 24
Reported as:
Number · participants
Part B: Drug Acceptability Assessment Using Modified Facial Hedonic Scale
participantsPart B: ELX/TEZ/IVA
Liked it Very Much16
Liked it a Little6
Not sure10
Disliked it a Little1
Disliked it Very Much0
SecondaryPart B: Number of Pulmonary Exacerbations Events

Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria. The total number of pulmonary exacerbations events across all participants were reported.

Time frame:
Part B: From Baseline Through Week 24
Reported as:
Number · pulmonary exacerbations events
Part B: Number of Pulmonary Exacerbations Events
pulmonary exacerbations eventsPart B: ELX/TEZ/IVA
Part B: Number of Pulmonary Exacerbations Events4
SecondaryPart B: Number of CF Related Hospitalizations

The total number of CF related hospitalization events across all participants were reported.

Time frame:
Part B: From Baseline Through Week 24
Reported as:
Number · hospitalizations
Part B: Number of CF Related Hospitalizations
hospitalizationsPart B: ELX/TEZ/IVA
Part B: Number of CF Related Hospitalizations0
SecondaryPart B: Ctrough of ELX, ELX Metabolite (M23-ELX), TEZ, TEZ Metabolite (M1-TEZ), IVA and IVA Metabolite (M1-IVA)
Time frame:
Part B: At Week 4
Reported as:
Mean · mcg/mL
Part B: Ctrough of ELX, ELX Metabolite (M23-ELX), TEZ, TEZ Metabolite (M1-TEZ), IVA and IVA Metabolite (M1-IVA)
mcg/mLPart B: ELX/TEZ/IVA
ELX: Week 4 (<30 kg)2.71 ± 1.77
ELX: Week 4 (>=30 kg)5.69 ± 3.00
M23-ELX: Week 4 (<30 kg)1.59 ± 1.24
M23-ELX: Week 4 (>=30 kg)4.41 ± 2.97
TEZ: Week 4 (<30 kg)1.43 ± 1.19
TEZ: Week 4 (>=30 kg)2.37 ± 1.07
M1-TEZ: Week 4 (<30 kg)5.57 ± 1.78
M1-TEZ: Week 4 (>=30 kg)8.12 ± 1.88
IVA: Week 4 (<30 kg)0.455 ± 0.681
IVA: Week 4 (>=30 kg)0.851 ± 0.489
M1-IVA: Week 4 (<30 kg)1.00 ± 0.630
M1-IVA: Week 4 (>=30 kg)2.18 ± 1.04
SecondaryPart B: Absolute Change in Lung Clearance Index 2.5 (LCI2.5)

LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

Time frame:
Part B: From Baseline Through Week 24
Reported as:
Least squares mean · lung clearance index
Part B: Absolute Change in Lung Clearance Index 2.5 (LCI2.5)
lung clearance indexPart B: ELX/TEZ/IVA
Part B: Absolute Change in Lung Clearance Index 2.5 (LCI2.5)-1.71 (-2.11 to -1.30)

Adverse events

Collected over Day 1 Through Safety Follow-up Visit (up to Day 43 for Part A, up to Week 28 for Part B). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: ELX/TEZ/IVA0/16 (0%)0/16 (0%)12/16 (75%)
Part B: ELX/TEZ/IVA0/66 (0%)1/66 (1.5%)62/66 (93.9%)
Most frequent serious events
Most frequent serious events
EventPart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Metapneumovirus infectionInfections and infestations0/161/66
PneumoniaInfections and infestations0/161/66
Rhinovirus infectionInfections and infestations0/161/66
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
CoughRespiratory, thoracic and mediastinal disorders5/1628/66
HeadacheNervous system disorders0/1616/66
PyrexiaGeneral disorders1/1614/66
Sputum increasedRespiratory, thoracic and mediastinal disorders3/163/66
RashSkin and subcutaneous tissue disorders3/168/66
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/1612/66
Upper respiratory tract infectionInfections and infestations0/1611/66
Nasal congestionRespiratory, thoracic and mediastinal disorders2/1610/66
Productive coughRespiratory, thoracic and mediastinal disorders2/165/66
Abdominal painGastrointestinal disorders1/168/66

Baseline characteristics

The analysis population included all enrolled participants who carry the intended CFTR allele mutation and received at least 1 dose of study drug in the respective part of the study.

Age, Categorical
Age, Categorical(Participants)ELX/TEZ/IVA
Part A (15 Days) — <=18 years16
Part A (15 Days) — Between 18 and 65 years0
Part A (15 Days) — >=65 years0
Part B (24 Weeks) — <=18 years66
Part B (24 Weeks) — Between 18 and 65 years0
Part B (24 Weeks) — >=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Part A (15 Days) — Female11
Part A (15 Days) — Male5
Part B (24 Weeks) — Female39
Part B (24 Weeks) — Male27
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ELX/TEZ/IVA
Part A (15 Days) — Hispanic or Latino0
Part A (15 Days) — Not Hispanic or Latino16
Part A (15 Days) — Unknown or Not Reported0
Part B (24 Weeks) — Hispanic or Latino0
Part B (24 Weeks) — Not Hispanic or Latino58
Part B (24 Weeks) — Unknown or Not Reported8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ELX/TEZ/IVA
Part A (15 Days) — American Indian or Alaska Native0
Part A (15 Days) — Asian0
Part A (15 Days) — Native Hawaiian or Other Pacific Islander0
Part A (15 Days) — Black or African American0
Part A (15 Days) — White16
Part A (15 Days) — More than one race0
Part A (15 Days) — Unknown or Not Reported0
Part B (24 Weeks) — American Indian or Alaska Native0
Part B (24 Weeks) — Asian0
Part B (24 Weeks) — Native Hawaiian or Other Pacific Islander0
Part B (24 Weeks) — Black or African American0
Part B (24 Weeks) — White57
Part B (24 Weeks) — More than one race1
Part B (24 Weeks) — Unknown or Not Reported8
08

Study locations

21 sites
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Northwell Health- Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
  • Clinical Research of Charlotte
    Charlotte, North Carolina 28277, United States
  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Queensland Children's Hospital
    South Brisbane, Australia
  • The Children's Hospital at Westmead
    Westmead, Australia
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia's Children's Hospital
    Vancouver, Canada
  • Children's Health Ireland at Crumlin
    Dublin, Ireland
  • Children's Health Ireland at Temple Street
    Dublin, Ireland
  • Birmingham Children's Hospital
    Birmingham, United Kingdom
  • Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital
    London, United Kingdom
09

References and documents

Publications

  • Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 Jun 15;203(12):1522-1532. doi: 10.1164/rccm.202102-0509OC. PubMed 33734030 ↗
  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2020, 22 months.

Results were first posted in Oct 2021, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 22 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2018
First posted
Oct 2, 2018
StartActual
Oct 2, 2018
Primary completionActual
Aug 7, 2020
CompletionActual
Aug 7, 2020
Results first posted
Oct 22, 2021
Last update
Oct 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03691779
Responsible party
Sponsor
First posted
Oct 2, 2018
Start date
Oct 2, 2018
Primary completion
Aug 7, 2020
Completion
Aug 7, 2020
Results posted
Oct 22, 2021
Last update
Oct 22, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion